You are here: Industry Insights > bluebird bio

News List

bluebird bio Amends CAR-T Collaboration Agreement contractpharma
May 19, 2020
Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-U.S. territories.
FDA refuse to file BMS/bluebird bio's CAR-T therapy pharmatimes
May 14, 2020
US regulators have refused to file Bristol Myers Squibb and bluebird bio's marketing application seeking approval of idecabtagene vicleucel (ide-cel) for patients with heavily pre-treated relapsed and refractory multiple myeloma.
Bristol Myers Squibb and bluebird bio submit BLA for Idecabtagene Vicleucel to FDA pharmaceutical-business-review
April 03, 2020
Bristol Myers Squibb and bluebird bio submitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
apceth Starts Commercial Manufacturing of Zynteglo™ ▼, bluebird bio’s Gene Therapy for Transfusion-Dependent β-Thalassemia b3cnewswire
January 17, 2020
apceth Biopharma GmbH, a subsidiary of Hitachi Chemical Co., Ltd. and a leading company for the manufacturing of cell and gene therapeutics, starts the commercial manufacturing of Zynteglo™ ▼, a product of bluebird bio, Inc. bluebird bio announced ...
apceth, bluebird bio Enter Mfg. Tie-up contractpharma
June 10, 2019
apceth to operate as the commercial manufacturer in Europe for Zynteglo, bluebird bio’s gene therapy for β-thalassemia.
EC grants conditional approval for bluebird bio’s Zynteglo pharmaceutical-technology
June 05, 2019
The European Commission (EC) has granted conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo for the treatment of transfusion-dependent β-thalassemia (TDT).
bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies firstwordpharma
May 10, 2019
New Collaboration with Seattle Children's Research Institute Targets New Immunotherapy Approaches to Acute Myeloid Leukemia
Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine drugs
May 08, 2019
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401 ...
Bluebird tees up its first gene therapy approval with Zynteglo thumbs-up in EU fiercepharma
April 02, 2019
Bluebird Bio’s development of a gene therapy to treat transfusion-dependent β-thalassemia (TDT) has been far from easy, but the final path to market is finally coming into view for the 27-year-old company.
ASH18: New data can’t lift Bluebird Bio’s depressed shares fiercebiotech
January 03, 2019
Bluebird Bio has been singing the praises of two new therapies at the annual American Society of Hematology, but although the data look solid so far, investors don’t seem to be fully on board with the program.......

Previous page 1 2 Next page